Simvastatin Does Not Influence the Intestinal P-glycoprotein and MPR2, and the Disposition of Talinolol After Chronic Medication in Healthy Subjects Genotyped for the ABCB1, ABCC2 and SLCO1B1 Polymorphisms

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2006 Mar 18

PMID 16542205

Citations 7

Authors

Annika Bernsdorf

Thomas Giessmann

Christiane Modess

Danilo Wegner

Stefanie Igelbrink

Ute Hecker

Sierk Haenisch

Ingolf Cascorbi

Bernd Terhaag

Werner Siegmund

Affiliations

Soon will be listed here.

Abstract

Aims: To evaluate whether simvastatin influences (i) the intestinal expression of P-glycoprotein (P-gp) and MRP2, and (ii) the disposition of the beta(1)-selective blocker talinolol, a substrate of these transporter proteins.

Methods: The disposition of talinolol after intravenous (30 mg) and single or repeated oral administration (100 mg daily) was monitored before and after chronic treatment with simvastatin (40 mg daily) in 18 healthy subjects (10 males, eight females, body mass index 19.0-27.0 kg m(-2)) genotyped for ABCB1, ABCC2 and SLCO1B1 polymorphisms. The steady-state pharmacokinetics of simvastatin was evaluated before and after repeated oral talinolol administration. The duodenal expression of ABCB1 and ABCC2 mRNA before and after simvastatin treatment was quantified using real-time reverse transcriptase-polymerase chain reaction (TaqMan.

Results: Simvastatin did not influence the expression of duodenal ABCB1 and ABCC2. There was no significant pharmacokinetic interaction between simvastatin and talinolol. Duodenal ABCB1 mRNA content was significantly correlated with the AUC(0-infinity) (r = 0.627, P = 0.039) and C(max) (r = 0.718, P = 0.013) of oral talinolol. The ABCB1 and ABCC2 gene polymorphisms did not influence simvastatin and talinolol disposition. The half-life of the latter was significantly shorter in the nine carriers with a SLCO1B1*1b allele compared with the seven subjects with the wild-type SLCO1B1*1a/*1a genotype (12.2 +/- 1.6 h vs. 14.5 +/- 1.4 h, P = 0.01).

Conclusions: Simvastatin does not influence the intestinal expression of P-gp and MRP2 in man. There was no pharmacokinetic interaction between talinolol and simvastatin during their chronic co-administration to healthy subjects.

Citing Articles

Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.

Asaumi R, Nunoya K, Yamaura Y, Taskar K, Sugiyama Y CPT Pharmacometrics Syst Pharmacol. 2022; 11(7):919-933.

PMID: 35570332 PMC: 9286720. DOI: 10.1002/psp4.12807.

The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins.

Murphy C, Deplazes E, Cranfield C, Garcia A Int J Mol Sci. 2020; 21(22).

PMID: 33228116 PMC: 7699354. DOI: 10.3390/ijms21228745.

Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.

Matthaei J, Tzvetkov M, Gal V, Sachse-Seeboth C, Sehrt D, Hjelmborg J Genome Med. 2016; 8(1):119.

PMID: 27825374 PMC: 5101708. DOI: 10.1186/s13073-016-0372-2.

Calorie Restriction Increases P-Glycoprotein and Decreases Intestinal Absorption of Digoxin in Mice.

Renaud H, Klaassen C, Csanaky I Drug Metab Dispos. 2016; 44(3):366-9.

PMID: 26744253 PMC: 4767382. DOI: 10.1124/dmd.115.064766.

Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Ma J, Tsunoda S, Bertino Jr J, Trivedi M, Beale K, Nafziger A Clin Pharmacokinet. 2010; 49(4):223-37.

PMID: 20214407 DOI: 10.2165/11318000-000000000-00000.

References

Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang W . A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999; 274(52):37161-8. DOI: 10.1074/jbc.274.52.37161. View

Schwarz U, Gramatte T, Krappweis J, Oertel R, Kirch W . P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther. 2000; 38(4):161-7. DOI: 10.5414/cpp38161. View

Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M . Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther. 2000; 68(1):6-12. DOI: 10.1067/mcp.2000.107579. View

Backman J, Kyrklund C, Kivisto K, Wang J, Neuvonen P . Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000; 68(2):122-9. DOI: 10.1067/mcp.2000.108507. View

Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R . Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther. 2000; 68(4):345-55. DOI: 10.1067/mcp.2000.109797. View

Kyrklund C, Backman J, Kivisto K, Neuvonen M, Laitila J, Neuvonen P . Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 2001; 68(6):592-7. DOI: 10.1067/mcp.2000.111414. View

Bogman K, Peyer A, Torok M, Kusters E, Drewe J . HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 2001; 132(6):1183-92. PMC: 1572659. DOI: 10.1038/sj.bjp.0703920. View

Wang E, Casciano C, Clement R, Johnson W . HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001; 18(6):800-6. DOI: 10.1023/a:1011036428972. View

Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U . Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001; 70(2):189-99. DOI: 10.1067/mcp.2001.117412. View

10.

Tirona R, Leake B, Merino G, Kim R . Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 2001; 276(38):35669-75. DOI: 10.1074/jbc.M103792200. View

11.

Boger R . Drug interactions of the statins and consequences for drug selection. Int J Clin Pharmacol Ther. 2001; 39(9):369-82. DOI: 10.5414/cpp39369. View

12.

Zschiesche M, Lemma G, Klebingat K, Franke G, Terhaag B, Hoffmann A . Stereoselective disposition of talinolol in man. J Pharm Sci. 2002; 91(2):303-11. DOI: 10.1002/jps.10054. View

13.

Sakaeda T, Takara K, Kakumoto M, Ohmoto N, Nakamura T, Iwaki K . Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J Pharm Pharmacol. 2002; 54(3):419-23. DOI: 10.1211/0022357021778493. View

14.

Siegmund W, Altmannsberger S, Paneitz A, Hecker U, Zschiesche M, Franke G . Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther. 2002; 72(3):256-64. DOI: 10.1067/mcp.2002.126706. View

15.

Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B . The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002; 72(5):572-83. DOI: 10.1067/mcp.2002.127739. View

16.

Najib N, Idkaidek N, Adel A, Admour I, Astigarraga R, De Nucci G . Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast and Zocor) in healthy human volunteers. Biopharm Drug Dispos. 2003; 24(5):183-9. DOI: 10.1002/bdd.347. View

17.

Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C . CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther. 2004; 75(3):213-22. DOI: 10.1016/j.clpt.2003.10.004. View

18.

Kim R . 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?. Clin Pharmacol Ther. 2004; 75(5):381-5. DOI: 10.1016/j.clpt.2004.01.004. View

19.

Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T . Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004; 75(5):415-21. DOI: 10.1016/j.clpt.2003.12.016. View

20.

Niemi M, Schaeffeler E, Lang T, Fromm M, Neuvonen M, Kyrklund C . High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004; 14(7):429-40. DOI: 10.1097/01.fpc.0000114750.08559.32. View